Genetic polymorphism of drug-metabolizing enzymes and susceptibility to oral cancer

被引:107
|
作者
Sato, M
Sato, T
Izumo, T
Amagasa, T
机构
[1] Tokyo Med & Dent Univ, Grad Sch, Bunkyo Ku, Tokyo 1138549, Japan
[2] Saitama Canc Ctr, Dept Clin Pathol, Ina, Saitama 3620806, Japan
关键词
D O I
10.1093/carcin/20.10.1927
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
An individual difference in the susceptibility to chemical carcinogens is one of the most important factors in the estimate of risk of human cancer. Recently, it has been reported that genetic risk for tobacco-related cancers is associated with polymorphisms of the CYP1A1 and GSTM1 genes in terms of genotype frequencies and cigarette smoking dose. In this study, we investigated the inter-individual difference in genetically determined susceptibility to oral squamous cell carcinoma (SCC) in relation to cigarette smoking dose in a Japanese population. DNA samples were obtained from both patients and controls, We identified individuals at high risk genetically for oral SCC in terms of polymorphisms of the CYP1A1 and GSTM1 genes. This study then compared the estimated total number of cigarettes smoked by patients with those smoked by controls. In this case-control study, we estimated the odds ratios of susceptible to non-susceptible individuals. CYP1A1 genotype C and GSTM1 deficiency were frequently found among oral SCC patients, Patients with genotype C and GSTM1 deficiency contracted carcinoma after fewer cigarettes than those with other genotypes, Individuals with these two genotypes were at remarkably high risk at a low dose level of cigarette smoking. Individual differences in polymorphisms of the CYP1A1 and GSTM1 genes is one important factor in the estimate of risk of oral SCC at a low dose level of cigarette smoking.
引用
收藏
页码:1927 / 1931
页数:5
相关论文
共 50 条
  • [1] Genetic polymorphisms of drug-metabolizing enzymes and susceptibility to oral cavity cancer
    Hahn, M
    Hagedorn, G
    Kuhlisch, E
    Schackert, HK
    Eckelt, U
    ORAL ONCOLOGY, 2002, 38 (05): : 486 - 490
  • [2] Polymorphism of drug-metabolizing enzymes in relation to individual susceptibility to industrial chemicals
    Nakajima, T
    Aoyama, T
    INDUSTRIAL HEALTH, 2000, 38 (02) : 143 - 152
  • [3] Genetic polymorphism of drug-metabolizing enzymes and styrene-induced DNA damage
    Buschini, A
    De Palma, G
    Poli, P
    Martino, A
    Rossi, C
    Mozzoni, P
    Scotti, E
    Buzio, L
    Bergamaschi, E
    Mutti, A
    ENVIRONMENTAL AND MOLECULAR MUTAGENESIS, 2003, 41 (04) : 243 - 252
  • [4] Genetic polymorphisms in drug-metabolizing enzymes and drug targets
    Hiratsuka, M
    Mizugaki, M
    MOLECULAR GENETICS AND METABOLISM, 2001, 73 (04) : 298 - 305
  • [5] Genetic polymorphism of drug metabolizing enzymes
    Yokoi, T
    Kamataki, T
    SEIKAGAKU, 1997, 69 (10): : 1196 - 1199
  • [6] Genetic polymorphisms of drug-metabolizing enzymes and the susceptibility to antituberculosis drug-induced liver injury
    Huang, Yi-Shin
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2007, 3 (01) : 1 - 8
  • [7] Drug-metabolizing enzymes: role in drug resistance in cancer
    Kaur, G.
    Gupta, S. K.
    Singh, P.
    Ali, V.
    Kumar, V.
    Verma, M.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2020, 22 (10): : 1667 - 1680
  • [8] Cancer and phase II drug-metabolizing enzymes
    Sheweita, SA
    Tilmisany, AK
    CURRENT DRUG METABOLISM, 2003, 4 (01) : 45 - 58
  • [9] Drug-metabolizing enzymes: role in drug resistance in cancer
    G. Kaur
    S. K. Gupta
    P. Singh
    V. Ali
    V. Kumar
    M. Verma
    Clinical and Translational Oncology, 2020, 22 : 1667 - 1680
  • [10] The clinical role of genetic polymorphisms in drug-metabolizing enzymes
    D Tomalik-Scharte
    A Lazar
    U Fuhr
    J Kirchheiner
    The Pharmacogenomics Journal, 2008, 8 : 4 - 15